Please try another search
Balaxi Pharmaceuticals Limited reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported sales was INR 547.21 million compared to INR 863.85 million a year ago. Revenue was INR 550.01 million compared to INR 905.23 million a year ago. Net income was INR 144.29 million compared to INR 154.87 million a year ago. Basic earnings per share from continuing operations was INR 14.1 compared to INR 15.49 a year ago. Diluted earnings per share from continuing operations was INR 14.06 compared to INR 15.49 a year ago.For the six months, sales was INR 1,206.76 million compared to INR 1,691.7 million a year ago. Revenue was INR 1,199.48 million compared to INR 1,765.92 million a year ago. Net loss was INR 269.14 million compared to net income of INR 296.33 million a year ago. Basic loss per share from continuing operations was INR 26.33 compared to basic earnings per share from continuing operations of INR 29.63 a year ago. Diluted loss per share from continuing operations was INR 26.1 compared to diluted earnings per share from continuing operations of INR 29.63 a year ago.
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Revenue | 607.85 | 547.21 | 659.55 | 806.81 |
Gross Profit | 304.24 | 256 | 256.42 | 296.02 |
Operating Income | 131.79 | 101.03 | 85.55 | 115.55 |
Net Income | 135.94 | 144.29 | -413.43 | 81 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Total Assets | 2144.72 | 2396.69 | ||
Total Liabilities | 590 | 567.89 | ||
Total Equity | 1554.72 | 1554.72 | 1828.8 | 1828.8 |
Period Ending: | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 |
---|---|---|---|---|
Period Length: | 0 Months | 0 Months | 0 Months | 0 Months |
Cash From Operating Activities | ||||
Cash From Investing Activities | ||||
Cash From Financing Activities | ||||
Net Change in Cash |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review